DeckTherapeutics, Inc.

DeckTherapeutics, Inc. is pioneering IV omega-3 therapeutics for prevention of acute hypoxic-ischemic injury. Omega-3s and their natural Specialized Pro-resolving Mediator (SPM) derivatives achieve their effectiveness through simultaneous regulation of several processes which are activated by hypoxia-ischemia and cause cell death and organ injury, such as mitochondrial failure, free radical generation and apoptosis. Our technology platform from Columbia University enables delivery of omega-3 to the brain within minutes. Potent neuroprotection has been demonstrated in neonatal, juvenile and adult rodent models at Columbia and at four collaborating labs. Our lead compound THDG3 is now being tested in neonatal lamb and piglet models of the serious rare pediatric disease neonatal hypoxic-ischemic encephalopathy (HIE), brain damage in newborns deprived of oxygen during labor/delivery. HIE is a main cause of cerebral palsy, epilepsy and low IQ in newborns. Our development efforts are supported by a world-class Scientific Advisory Board and clinical advisors.

Website

https://www.decktherapeutics.com/

External link for DeckTherapeutics, Inc.

Industry

Biotechnology Research

Company size

2-10 employees

Headquarters

New York, New York

Type

Privately Held

Specialties

Orphan drugs, Neuroprotection, Omega-3, Neonatal, Hypoxia-ischemia, Diglyceride, EPA, DHA, Rare pediatric disease, Cerebral palsy, Epilepsy, and Hypoxic-ischemic injury